Pressure BioSciences (PBIO) Stock Price, News & Analysis

Company Overview

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and the Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. The company was incorporated in 1978 and is based in South Easton, Massachusetts.

Key Stats

• Today's Range: $0.0031 to $0.0031
• 50-Day Range: $0.0031 to $0.0135
• 52-Week Range: $0.00 to $0.27
• Volume: N/A
• Average Volume: 6,877 shs
• Market Capitalization: $133,197.70
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Pressure BioSciences Stock Analysis - MarketRank™

Pressure BioSciences scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Pressure BioSciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Pressure BioSciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pressure BioSciences is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Pressure BioSciences has been sold short.

Short Interest Ratio / Days to Cover

Pressure BioSciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pressure BioSciences does not currently pay a dividend.

Dividend Growth

Pressure BioSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the float of Pressure BioSciences has been sold short.

Short Interest Ratio / Days to Cover

Pressure BioSciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Pressure BioSciences this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pressure BioSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.80% of the stock of Pressure BioSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.02% of the stock of Pressure BioSciences is held by institutions.

PBIO Stock Analysis - Frequently Asked Questions

How have PBIO shares performed this year?

Pressure BioSciences' stock was trading at $0.0035 at the beginning of 2025. Since then, PBIO shares have decreased by 11.4% and is now trading at $0.0031.
View the best growth stocks for 2025 here.

How were Pressure BioSciences' earnings last quarter?

Pressure BioSciences, Inc. (OTCMKTS:PBIO) released its quarterly earnings data on Friday, February, 7th. The company reported ($0.15) EPS for the quarter.

How do I buy shares of Pressure BioSciences?

Shares of PBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pressure BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pressure BioSciences investors own include Hydrofarm Holdings Group (HYFM), Advanced Micro Devices (AMD), Monaker Group (MKGI), Meta Materials (MMAT), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP) and Novavax (NVAX).

Company Calendar

• Last Earnings: 2/07/2025
• Today: 4/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Measuring And Control Equipment
• Current Symbol: OTCMKTS:PBIO
• CIK: 830656
• Web: www.pressurebiosciences.com
• Phone: 508-230-1828
• Fax: 508-230-1829
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-29,310,000.00
• Net Margins: -2,053.81%
• Pretax Margin: -2,053.68%
• Return on Equity: N/A
• Return on Assets: -743.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.02
• Quick Ratio: 0.01

Sales & Book Value

• Annual Sales: $1.98 million
• Price / Sales: 0.07
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.29) per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 42,967,000
• Free Float: 36,543,000
• Market Cap: $133,197.70
• Optionable: Not Optionable
• Beta: -0.46